Moreover, in an in vivo experiment of an ER+/HER2− PDX, single-agent birinapant significantly decreased tumor growth and the combination of birinapant and fulvestrant was superior with complete tumor regression in 4 of the 5 mice (Fig. 6C; Supplementary Fig. S7A–S7D). Here, ESR1 is linked to neoplasm.